Table 5 |
|||
|
Serologies of ankylosing spondylitis patients and healthy controls |
|||
|
Healthy controls (all) versus AS patients (all) |
|||
|
|
|||
|
Median healthy controls (all) |
Median AS patients (all) |
P value |
|
|
|
|||
|
IgA ASCA (ELISA units) |
0.4 |
0.5 |
0.737 |
|
IgG ASCA (ELISA units) |
6.7 |
6.6 |
0.597 |
|
I2 (ELISA units) |
5.7 |
6 |
0.685 |
|
OmpC (ELISA units) |
5.7 |
6.4 |
0.473 |
|
Cbir1 Fla (ELISA units) |
15.9 |
19.8 |
0.223 |
|
ANCA (ELISA units) |
4.3 |
6.9 |
0.003 |
|
|
|||
|
ANCA, antineutrophil cytoplasmic antibodies; AS, ankylosing spondylitis; ASCA, anti-Saccharomyces cerevisiae antibody; CBir1, anti-flagellin; OmpC, anti-Escherichia coli outer membrane porin C. |
|||
|
Matzkies et al. Arthritis Research & Therapy 2012 14:R261 doi:10.1186/ar4106 |
|||